FIELD: medicine, dermatology, pharmacy.
SUBSTANCE: invention relates to using cyclopamine in treatment of psoriasis and for preparing a drug wherein the concentration of cyclopamine is 18 mM for inducing differentiation of skin epidermal cells damaged by psoriasis. Invention shows rapid cleaning patient skin from psoriatic injuries and without significant adverse effects. Disappearance of clinical symptoms of psoriasis including erythema and squamas in patients accompanies with recovery of histopathological features to the normal state and can be achieved in topical using the drug during a day. Another specific feature of cyclopamine is the absence of hazard effect on health skin for 14 months of medicinal observation.
EFFECT: valuable properties and enhanced effectiveness of drug.
5 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USING CYCLOPAMINE IN TREATMENT OF BASAL CELL EPITHELIOMA (CARCINOMA) AND OTHER TUMORS | 2001 |
|
RU2308948C2 |
| TREATMENT OF INFLAMMATORY SKIN DISEASES | 2013 |
|
RU2662564C2 |
| METHOD FOR DIAGNOSING DEVERGIS'S LICHEN RUBER PILARIS | 1995 |
|
RU2096783C1 |
| USE OF N-(6,8,8-TRIMETHYL-8,9-DIHYDROFURO[3,2-H]QUINOLIN-5-YL)ACETAMIDE AS AN AGENT FOR PHOTOTHERAPY OF PSORIASIS AND PSORIATIC ARTHRITIS | 2018 |
|
RU2686692C1 |
| TETRAPEPTIDES OBTAINED FROM HUMAN SYNTHETIC CHEMICALS SUITABLE FOR TREATING DIFFERENT SKIN CONDITIONS | 2014 |
|
RU2687151C2 |
| COMPOSITION FOR PSORIASIS TREATMENT | 2000 |
|
RU2225717C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PLAQUE PSORIASIS WITH OTHER CHRONIC SKIN DISEASES | 2019 |
|
RU2703314C1 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| METHOD FOR DIAGNOSING ERYTHRODERMIC PSORIASIS | 2015 |
|
RU2611350C1 |
| MEDICATIONS FOR TREATING PEMPHIGUS CONTAINING ANTIBODIES TO Fas-LIGAND | 2008 |
|
RU2558260C2 |
